Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagenase ointment versus hydrogel dressing for chronic refractory wounds
ChiCTR2400086236Phase 4Recruiting
- Sponsor
- Fourth Medical Center of PLA General Hospital
- Start
- Jun 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of collagenase clostridium histolyticum in refractory chronic wound (RCW), diabetic foot ulcer (DFU), stasis ulcer and 1 more (2 arms), sponsored by Fourth Medical Center of PLA General Hospital. Primary endpoint: Percentage change in wound area at week 8 compared with baseline. Started Jun 2024; status: recruiting.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
refractory chronic wound (RCW)diabetic foot ulcer (DFU)stasis ulcerdecubitus ulcer
Beyond the preview
Go deeper on ChiCTR2400086236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086236.